F. Hodi

Oncology · 2008–2023

A researcher in the Science corpus: 36 papers; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 397 citations into it; #1,141 of 1,698 by trust here, #13 by citations
• Immunology — 248 citations into it

Whom F. Hodi trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Pardoll
2. J. Wolchok
3. C. Robert
4. Antoni Ribas

Who trusts F. Hodi overall

1. Anand Rotte
2. J. Wolchok
3. Padmanee Sharma
4. C. Robert
5. A. Schietinger
6. M. Postow
7. J. Haanen
8. K. Palucka
9. Antoni Ribas
10. E. Buchbinder

Papers from F. Hodi's perspective

Ordered by how strongly the researchers F. Hodi trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
3. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (Journal of Experimental Medicine)
4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
5. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
6. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (Proceedings of the National Academy of Sciences of the United States of America)
7. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
8. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
9. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (Science)
10. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (New England Journal of Medicine)

Their papers

• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. (2014) — 1,629 citations
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (2010) — 14,544 citations
• Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma (2015) — 4,132 citations
• BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma (2013) — 890 citations
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) — 2,546 citations
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015) — 2,625 citations
• Hepatotoxicity with combination of vemurafenib and ipilimumab. (2013) — 697 citations
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) — 1,024 citations
• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) — 985 citations
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016) — 1,211 citations
• Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) — 1,184 citations
• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) — 1,526 citations
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. (2012) — 1,045 citations
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) — 2,934 citations
• CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013) — 646 citations
• Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma (2022) — 1,394 citations
• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) — 808 citations
• The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) — 482 citations
• Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade (2019) — 1,754 citations
• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019) — 814 citations